These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30778344)

  • 1. Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System.
    Marín Morales JM; Münch N; Peter K; Freund D; Oelschlägel U; Hölig K; Böhm T; Flach AC; Keßler J; Bonifacio E; Bornhäuser M; Fuchs A
    Front Immunol; 2019; 10():38. PubMed ID: 30778344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation.
    Peters JH; Preijers FW; Woestenenk R; Hilbrands LB; Koenen HJ; Joosten I
    PLoS One; 2008 Sep; 3(9):e3161. PubMed ID: 18776930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.
    Mock U; Nickolay L; Philip B; Cheung GW; Zhan H; Johnston ICD; Kaiser AD; Peggs K; Pule M; Thrasher AJ; Qasim W
    Cytotherapy; 2016 Aug; 18(8):1002-1011. PubMed ID: 27378344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity.
    Ukena SN; Höpting M; Velaga S; Ivanyi P; Grosse J; Baron U; Ganser A; Franzke A
    Exp Hematol; 2011 Dec; 39(12):1152-60. PubMed ID: 21864487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration.
    Malakhova E; Pershin D; Kulakovskaya E; Vedmedskaia V; Fadeeva M; Lodoeva O; Sozonova T; Muzalevskii Y; Kazachenok A; Belchikov V; Shelikhova L; Molostova O; Volkov D; Maschan M
    Cytotherapy; 2024 Jun; 26(6):567-578. PubMed ID: 38493403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
    Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
    Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical-grade regulatory T cells: Comparative analysis of large-scale expansion conditions.
    Velaga S; Alter C; Dringenberg U; Thiesler CT; Kuhs S; Olek S; Ukena SN; Franzke A
    Exp Hematol; 2017 Jan; 45():27-35.e1. PubMed ID: 27693388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
    Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
    Front Immunol; 2019; 10():2361. PubMed ID: 31649672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
    Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
    Front Immunol; 2020; 11():482. PubMed ID: 32528460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR-T cell expansion platforms yield distinct T cell differentiation states.
    Song HW; Prochazkova M; Shao L; Traynor R; Underwood S; Black M; Fellowes V; Shi R; Pouzolles M; Chou HC; Cheuk AT; Taylor N; Jin P; Somerville RP; Stroncek DF; Khan J; Highfill SL
    Cytotherapy; 2024 Jul; 26(7):757-768. PubMed ID: 38625071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response.
    Singh AK; Seavey CN; Horvath KA; Mohiuddin MM
    Xenotransplantation; 2012; 19(2):102-11. PubMed ID: 22497512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.
    Lock D; Mockel-Tenbrinck N; Drechsel K; Barth C; Mauer D; Schaser T; Kolbe C; Al Rawashdeh W; Brauner J; Hardt O; Pflug N; Holtick U; Borchmann P; Assenmacher M; Kaiser A
    Hum Gene Ther; 2017 Oct; 28(10):914-925. PubMed ID: 28847167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis.
    Keever-Taylor CA; Browning MB; Johnson BD; Truitt RL; Bredeson CN; Behn B; Tsao A
    Cytotherapy; 2007; 9(2):144-57. PubMed ID: 17453966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale Isolation of Highly Pure "Untouched" Regulatory T Cells in a GMP Environment for Adoptive Cell Therapy.
    Haase D; Puan KJ; Starke M; Lai TS; Soh MY; Karunanithi I; San Luis B; Poh TY; Yusof N; Yeap CH; Phang CY; Chye WS; Chan M; Koh MB; Goh YT; Bertin-Maghit S; Nardin A; Ho LP; Rotzschke O
    J Immunother; 2015; 38(6):250-8. PubMed ID: 26049548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells.
    He X; Landman S; Bauland SC; van den Dolder J; Koenen HJ; Joosten I
    PLoS One; 2016; 11(5):e0156311. PubMed ID: 27224512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmented Expansion of Treg Cells From Healthy and Autoimmune Subjects
    Reading JL; Roobrouck VD; Hull CM; Becker PD; Beyens J; Valentin-Torres A; Boardman D; Lamperti EN; Stubblefield S; Lombardi G; Deans R; Ting AE; Tree T
    Front Immunol; 2021; 12():716606. PubMed ID: 34539651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoid hormone differentially modulates the in vitro expansion and cytokine profile of thymic and splenic Treg cells.
    Pap R; Ugor E; Litvai T; Prenek L; Najbauer J; Németh P; Berki T
    Immunobiology; 2019 Mar; 224(2):285-295. PubMed ID: 30612787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.
    Theil A; Tuve S; Oelschlägel U; Maiwald A; Döhler D; Oßmann D; Zenkel A; Wilhelm C; Middeke JM; Shayegi N; Trautmann-Grill K; von Bonin M; Platzbecker U; Ehninger G; Bonifacio E; Bornhäuser M
    Cytotherapy; 2015 Apr; 17(4):473-86. PubMed ID: 25573333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.